AbCellera Biologics Inc. (ABCL) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped ABCL stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: AbCellera Biologics Inc. showcases significant promise as a cutting-edge player in antibody therapeutics and biologics discovery. With strong analyst consensus (STRONG BUY), ambitious revenue growth, and recent collaborations bolstering its prospects, the company is poised for substantial growth over the short and long term. Despite inherent risks tied to regulatory hurdles and market volatility, AbCellera's innovative approach and expanding market presence enhance its attractiveness to investors. The saved 1-year distribution is P10 $4.5, P50 $8.5, and P90 $12.
Last analyzed · Model: gpt-4o
AbCellera Biologics Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $4.5 | Pessimistic plausible scenario |
| P50 | $8.5 | Median scenario |
| P90 | $12 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
The strong analyst consensus (STRONG BUY) and impressive revenue growth estimate indicate a high likelihood of appreciation in the short term. With collaborations expanding and positive cancer therapy trial results, bullish scenarios are well-supported.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this ABCL analysis generated?
June 7, 2026.
Is this a guaranteed ABCL prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full ABCL stock analysis · ABCL sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.